The EMAW team integrates clinical trial leaders, leading CNS drug developers, industry experts and AI and other subject matters experts
We understand the value of experience in designing trials, configuring platforms and using data and technology intentionally to meet sponsor needs
Who we are
Built by people who have dedicated their professional lives to enhancing clinical research
Founded in 2018, EMA Wellness is founder owned and operated and committed to sponsor collaboration and partnerships.
Founders and operators
Committed professionals with a proven track record executing
Colin Bower
CEO / CO-FOUNDERFounder and leader of 4 clinical trial technology companies improving clinical trials for 15+ years.
Commercial leadership
Dr. Andrew Cutler
CHIEF MEDICAL OFFICERCNS clinical site owner and leader; author of over 200 peer-reviewed scientific publications.
Medical leadership
Dan DeBonis
HEAD OF PRODUCTCo-founder of Concordant Rater Systems and Signant product leader, developing eCOA for 20+ years.
eCOA product depth
Gordon Kessler
DATA PRIVACY OFFICERFounder and General Counsel Officer at AiCure, with nearly 20 years of patent law experience.
Privacy and IP
Stephen Saber
CTO / CO-FOUNDERTechnology leader successfully scaling four technology platforms in the last 20 years.
Technology scale-up
Julia Gapour
Senior Director, Quality ManagementScientific founders and advisors
Exceptional track records in CNS drug development
Key opinion leaders and subject matter experts combine to collaborate with sponsor partners
Dr. Charles Nemeroff
SCIENTIFIC FOUNDERChair and Professor at Dell Medical School with decades of leadership in psychiatry and psychedelic research.
Dr Philip Harvey, MD
SCIENTIFIC FOUNDERLeonard M. Miller Professor of Psychiatry focused on cognition, functioning, and CNS outcomes.
Dr Pierre N. Tariot, MD
SCIENTIFIC ADVISORDirector Emeritus of Banner Alzheimer’s Institute and Alzheimer’s prevention research leader.
Dr. Leslie Shinobu
SCIENTIFIC ADVISORScientific advisor listed on the Q1 2026 EMA Wellness organization chart.
Dr Alan Schatzberg, MD
SCIENTIFIC ADVISORFormer APA and ACNP President; Stanford psychiatry leader and mood disorders expert.
Dr Ned Kalin, MD
SCIENTIFIC ADVISOREditor-in-Chief of the American Journal of Psychiatry and leader in emotion and anxiety research.
Dr Sanjay Mathew, MD
SCIENTIFIC ADVISORProfessor and Chairman of the Department of Psychiatry and Behavioral Medicine at Texas A&M University College of Medicine.
Dr. Hubert Fernandez
SCIENTIFIC ADVISORExecutive advisor and KOL listed on the Q1 2026 EMA Wellness organization chart.
Executive Advisors
Dr Stephen Brannan, MD
EXECUTIVE ADVISORFormer Karuna Therapeutics CMO with CNS development and approval leadership experience.
Dr Raymond Sanchez, MD
EXECUTIVE ADVISORFormer Cerevel CMO with 20+ years in psychiatric and pharmaceutical development.
Jason Martin
EXECUTIVE ADVISORFormer Signant COO, Parexel Head of Informatics and Medidata product lead
Why this matters
EMAW as an engaged and trusted partner
Work with our team to design your trial, configure our platform to meet specific trial needs and objectives and interrogate data for endpoint reliability and insights
Scientific authority
Expertise across psychiatry, neuroscience, Alzheimer’s disease, schizophrenia, mood disorders, and CNS development.
Endpoint integrity
Clinical and scientific leadership reinforcing quality, validity, reliability, and data interpretation.
Explore the EMA Wellness platform.
Return to the Home page to review the complete platform story.
Return to Home →